
Rybrevant Faspro is approved for certain adults with recurrent or metastatic head and neck squamous cell carcinoma after specified prior treatments.
Eligible adults have HNSCC that returned or spread and progressed on or after both platinum-based chemotherapy and immunotherapy.
The indication does not include oropharyngeal squamous cell carcinoma associated with human papillomavirus, also called HPV.
An open-label, multicenter trial involving 102 patients reported an overall response rate of 42%; response meant tumors shrank or disappeared.
Among patients who responded, 56% had responses lasting at least six months; this figure applies to responders, not everyone enrolled.
Here, accelerated approval relied on tumor response; long-term benefit remains unconfirmed, so confirmatory studies are required.
Warnings include hypersensitivity and administration reactions, lung inflammation, skin reactions, eye toxicity, and potential harm to an unborn baby.
Read the FDA announcement for more information about the approval, trial results, eligibility, and required follow-up studies.